Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).

被引：0

作者：

Amonkar, Mayur

Gomez-Ulloa, David

Kothari, Smita

Cheung, Winson Y.

Chau, Ian

Zalcberg, John Raymond

Lara, Nuria

Falcone, Alfredo

机构：

[1] Merck & Co Inc, N Wales, PA USA

[2] IQVIA, Barcelona, Spain

[3] Merck & Co Inc, Ctr Observat & Real World Evidence, Kenilworth, NJ USA

[4] BC Canc Agcy, Vancouver, BC, Canada

[5] Royal Marsden Hosp, London, England

[6] Royal Marsden Hosp, Sutton, Surrey, England

[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[8] IQVIA Real World Insights, Basel, Switzerland

[9] Azienda Osped Univ Pisana, Ist Toscano Tumori, Dept Translat Res & New Technol Med & Surg, Unit Med Oncol 2, Pisa, Italy

来源：

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.102

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

102

引用

页数：2